Logistic regression analysis.

<p>Outcome: Biopsy-proven HSIL.</p

Predictive values for the diagnosis of biopsy-proven HSIL.

<p>Predictive values for the diagnosis of biopsy-proven HSIL.</p

Predictive values for the diagnosis of biopsy-proven HSIL.

<p>Predictive values for the diagnosis of biopsy-proven HSIL.</p

General characteristics of the study population.

<p>General characteristics of the study population.</p

ROC area for diagnosis of biopsy proven-HSIL of the combination of the standard cytology with P16/Ki67 immunostaining vs. standard cytology alone.

<p>ROC area for diagnosis of biopsy proven-HSIL of the combination of the standard cytology with P16/Ki67 immunostaining vs. standard cytology alone.</p

Frequencies of P16/Ki67 positive immunostaining according to histologic results.

<p>Frequencies of P16/Ki67 positive immunostaining according to histologic results.</p

Sociodemographic characteristics of 4124 patients with follow-up HCVtest or more than two years of follow-up: prevalence of repeated HCV tests and multivariable logistic regression for the odds ratio (OR) of having a subsequent HCV serology.

<p>Sociodemographic characteristics of 4124 patients with follow-up HCVtest or more than two years of follow-up: prevalence of repeated HCV tests and multivariable logistic regression for the odds ratio (OR) of having a subsequent HCV serology.</p

Time trends of rates of HCV diagnoses, HCV infections and of follow-up HCV tests, 2004–2011.

<p>Time trends of rates of HCV diagnoses, HCV infections and of follow-up HCV tests, 2004–2011.</p

Rates and associated risk factors of HCV infection.

<p>*The table shows all the variables included in the final multivariables models.</p><p>Rates and associated risk factors of HCV infection.</p

Evolution of follow-up HCV testing rates, of HCV diagnosis rates and of HCV infection rates (per 100 person-years).

<p>Evolution of follow-up HCV testing rates, of HCV diagnosis rates and of HCV infection rates (per 100 person-years).</p